ARCHIVES

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

This article is from The Cancer Letter archive.

Vol. 32 No. 37 | October 20, 2006

Download PDF Visit The Full Archive

Related Articles

DCPC Board Ponders Screening Recommendations: Should NCI Have Policies? If So, What Will They Be?

September 26, 1986

Compendia Publishers Must Tell CMS How They Manage Conflicts Of Interest

November 13, 2009

European Agency Recommends Transfusions Over ESAs For Cancer Patients With Longer Life Expectancy.

June 27, 2008

Cancer Death Rate Declines, Clark Tells Science Writers

April 8, 1977

Nurse Oncology Society Growing, developing Care Guidelines

August 19, 1977

Healy ‘Concerned’ About NCI Budget; ‘Definite Erosion’

May 3, 1991